Bio-Light Israeli (BLGTY) 47.1700 $BLGTY
BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
PR Newswire - Thu May 19, 7:59AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT), ("BioLight" or the "Company"
, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that it has obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications. The product was in-licensed by BioLight from Fischer Pharmaceuticals Ltd. and RAMOT, the technology transfer arm of the Tel Aviv University. The product has CE Mark marketing approval in Europe, and BioLight is currently evaluating the clinical and regulatory efforts required to commercialize it in other territories around the world.
BOLT: ()
BioLight Reports Positive Second Clinical Study Results for its TeaRx(TM) Multi-Assay Test for Dry Eye Syndrome
PR Newswire - Thu Jan 07, 6:00AM CST
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company", an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today the completion of a successful U.S. clinical study that was designed to assess the effectiveness of its TeaRx(TM) multi-assay test in evaluating tears' components of healthy subjects as well as of patients suffering from dry eye syndrome ("DES".
BioLight Announces First IOPtiMate(TM) System Sale in Portugal
PR Newswire - Tue Dec 08, 8:23AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Portugal.
BioLight Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Dec 01, 6:00AM CST
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, today reported operational and financial results for the third quarter ended September 30, 2015.
BioLight Announces Partnership With Axella Research For CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer
PR Newswire - Mon Nov 30, 6:00AM CST
BioLight Life Sciences Investments (OTCQX:BLGTY, TASE:BOLT) ("BioLight" or the "Company", announced today that its cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC) ("Micromedic", has entered into a Collaboration Agreement (the "Agreement" with Axella Research LLC ("Axella", to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.
BioLight Announces Joint Investment in IOPtima Subsidiary
PR Newswire - Wed Nov 25, 6:00AM CST
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement" with two Asia-based venture capital firms (the "New Investors", pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary ("IOPtima" via a private placement. The financing will help IOPtima to continue the global commercialization of its innovative IOPtimate(TM) system used in the treatment of glaucoma, as well as to initiate a regulatory approval pathway process for the IOPtimate(TM) system with the U.S. Food and Drug Administration, commencing 2016.
BioLight's Eye-D Technology to be Featured at the 5th Annual Partnership Opportunities in Drug Delivery Conference in Boston
PR Newswire - Thu Sep 24, 7:17AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its Eye-D platform insert will be presented at the 5th Annual Partnership Opportunities in Drug Delivery ("PODD" conference on Monday, October 5, 2015 at 2:00 p.m. Eastern Time at the Boston Intercontinental Hotel in Boston, MA.
PFE: 35.31 (+0.06)
BioLight Reports Second Quarter 2015 Financial Results
PR Newswire - Tue Sep 01, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015.
BioLight Announces First IOPtiMate(TM) System Sale in Peru
PR Newswire - Thu Aug 13, 8:28AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Peru.
BioLight Announces Upcoming Change of ADS Conversion Ratio
PR Newswire - Thu Jul 23, 5:41AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that, in accordance with recently obtained shareholder approval for a 1-for-10 reverse split of its ordinary shares ("Shares", it will change its American Depositary Share ("ADS" to Share ratio from one (1) ADS representing one hundred (100) Shares to one (1) ADS representing ten (10) Shares, effective August 3, 2015. No action with regard to the ratio change is required from the holders of the ADSs.
BioLight Announces Collaboration With Ora, Inc. for TeaRx(TM) Multi-Parameter Diagnostic Test for Dry Eye Syndrome
PR Newswire - Mon Jun 15, 7:58AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE:BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced that it has expanded its relationship with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, via the signing of a Collaboration Agreement (the "Agreement" pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx(TM) multi-parameter diagnostic test for dry eye syndrome ("DES".
BioLight Reports First Quarter 2015 Financial Results
PR Newswire - Mon Jun 01, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company", a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015.
BioLight Announces Closing of Upsized US$6.6 Million Private Placement
PR Newswire - Tue May 12, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that it has completed an upsized private placement as part of the strategic partnership with Rock-One International Holdings Ltd for aggregate gross proceeds of US$6.6 million.
BioLight Announces First IOPtiMate(TM) System Sale in Hungary
PR Newswire - Mon Apr 13, 6:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Hungary.
BOLT: ()
BioLight Announces First IOPtiMate(TM) System Sale in Poland
PR Newswire - Mon Dec 01, 8:00AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system to a medical center located in Poland following a successful product trial.
Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman", a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target.
BOLT: ()
BioLight to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Wed Oct 22, 9:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Suzana Nahum-Zilberberg, CEO, and Itai Bar Natan, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central in New York, NY.
BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
PR Newswire - Thu May 19, 7:59AM CDT
BioLight Life Sciences Ltd. (TASE: BOLT), ("BioLight" or the "Company"
, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that it has obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications. The product was in-licensed by BioLight from Fischer Pharmaceuticals Ltd. and RAMOT, the technology transfer arm of the Tel Aviv University. The product has CE Mark marketing approval in Europe, and BioLight is currently evaluating the clinical and regulatory efforts required to commercialize it in other territories around the world. BOLT: ()
BioLight Reports Positive Second Clinical Study Results for its TeaRx(TM) Multi-Assay Test for Dry Eye Syndrome
PR Newswire - Thu Jan 07, 6:00AM CST
BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"
, an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today the completion of a successful U.S. clinical study that was designed to assess the effectiveness of its TeaRx(TM) multi-assay test in evaluating tears' components of healthy subjects as well as of patients suffering from dry eye syndrome ("DES". BioLight Announces First IOPtiMate(TM) System Sale in Portugal
PR Newswire - Tue Dec 08, 8:23AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Portugal. BioLight Reports Third Quarter 2015 Financial Results
PR Newswire - Tue Dec 01, 6:00AM CST
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"
, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, today reported operational and financial results for the third quarter ended September 30, 2015. BioLight Announces Partnership With Axella Research For CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer
PR Newswire - Mon Nov 30, 6:00AM CST
BioLight Life Sciences Investments (OTCQX:BLGTY, TASE:BOLT) ("BioLight" or the "Company"
, announced today that its cancer diagnostics subsidiary, Micromedic Technologies (TASE:MCTC) ("Micromedic", has entered into a Collaboration Agreement (the "Agreement" with Axella Research LLC ("Axella", to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States. BioLight Announces Joint Investment in IOPtima Subsidiary
PR Newswire - Wed Nov 25, 6:00AM CST
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"
, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement" with two Asia-based venture capital firms (the "New Investors", pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary ("IOPtima" via a private placement. The financing will help IOPtima to continue the global commercialization of its innovative IOPtimate(TM) system used in the treatment of glaucoma, as well as to initiate a regulatory approval pathway process for the IOPtimate(TM) system with the U.S. Food and Drug Administration, commencing 2016. BioLight's Eye-D Technology to be Featured at the 5th Annual Partnership Opportunities in Drug Delivery Conference in Boston
PR Newswire - Thu Sep 24, 7:17AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its Eye-D platform insert will be presented at the 5th Annual Partnership Opportunities in Drug Delivery ("PODD" conference on Monday, October 5, 2015 at 2:00 p.m. Eastern Time at the Boston Intercontinental Hotel in Boston, MA. PFE: 35.31 (+0.06)
BioLight Reports Second Quarter 2015 Financial Results
PR Newswire - Tue Sep 01, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015. BioLight Announces First IOPtiMate(TM) System Sale in Peru
PR Newswire - Thu Aug 13, 8:28AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Peru. BioLight Announces Upcoming Change of ADS Conversion Ratio
PR Newswire - Thu Jul 23, 5:41AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that, in accordance with recently obtained shareholder approval for a 1-for-10 reverse split of its ordinary shares ("Shares", it will change its American Depositary Share ("ADS" to Share ratio from one (1) ADS representing one hundred (100) Shares to one (1) ADS representing ten (10) Shares, effective August 3, 2015. No action with regard to the ratio change is required from the holders of the ADSs. BioLight Announces Collaboration With Ora, Inc. for TeaRx(TM) Multi-Parameter Diagnostic Test for Dry Eye Syndrome
PR Newswire - Mon Jun 15, 7:58AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE:BOLT) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced that it has expanded its relationship with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, via the signing of a Collaboration Agreement (the "Agreement" pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx(TM) multi-parameter diagnostic test for dry eye syndrome ("DES". BioLight Reports First Quarter 2015 Financial Results
PR Newswire - Mon Jun 01, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"
, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the first quarter ended March 31, 2015. BioLight Announces Closing of Upsized US$6.6 Million Private Placement
PR Newswire - Tue May 12, 6:00AM CDT
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that it has completed an upsized private placement as part of the strategic partnership with Rock-One International Holdings Ltd for aggregate gross proceeds of US$6.6 million.
BioLight Announces First IOPtiMate(TM) System Sale in Hungary
PR Newswire - Mon Apr 13, 6:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate(TM) system to a medical center located in Hungary.
BOLT: ()
BioLight Announces First IOPtiMate(TM) System Sale in Poland
PR Newswire - Mon Dec 01, 8:00AM CST
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announces the first sale of an IOPtiMate(TM) system to a medical center located in Poland following a successful product trial.
Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
Thomson Reuters ONE - Thu Oct 30, 8:00AM CDT
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (OTCQX: BLGTY) with a Buy rating and a $12.00 price target. BOLT: ()
BioLight to Present at the Canaccord Genuity 2014 Medical Technology and Diagnostics Forum
PR Newswire - Wed Oct 22, 9:00AM CDT
BioLight Life Sciences Investments Ltd. (TASE: BOLT, OTCQX:BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Suzana Nahum-Zilberberg, CEO, and Itai Bar Natan, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central in New York, NY.
